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ABSTRACT
Understanding the interactions between human 
immune cells and tumors is paramount when 
devising treatment strategies that prevent tumor 
evasion of immune cells and improve cytotoxic 
responses. NSG™* and NSG™-SGM3* mice are 
a proven host for engraftment of human tumors 
or establishment of human immunity following 
hematopoietic stem cell transplantation. Here, we 
provide evidence that NSG and NSG-SGM3 mice 
engrafted with hematopoietic stem cells (collectively 
referred to here as “humanized NSG mice”) can 
support the growth of allogeneic human tumors. 
The human tumors respond to standard-of-care 
chemotherapeutics, targeted therapies, and to 
immune check-point inhibitors clinically proven 
to initiate cytotoxic activity towards the tumor. 
Tumor-bearing, humanized NSG mice (the Onco-
Hu™* mouse offered exclusively from The Jackson 
Laboratory) are a new and valuable preclinical 
testing platform for immuno-oncology.
JAX® MICE, CLINICAL AND RESEARCH SERVICES
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These results 
support the use 
of humanized NSG 
and NSG-SGM3 
mice as a new 
preclinical bridge 
for immuno-
oncology therapies.
Immuno-Oncology: 
A New Paradigm 
for Patient Care
The traditional approach to cancer 
treatment utilizes broad-acting 
chemical agents that are toxic 
to rapidly dividing cells. This 
chemotherapeutic approach can 
be successful but is complicated 
by an array of off-target toxicities 
and risks inducing drug resistance. 
Targeted therapies are emerging as 
new standards-of-care (SOCs) but 
often result in resistances that leave 
room for improvement. Mammalian 
immune systems have efficient, 
highly specific mechanisms for 
eliminating pathogen-infected cells 
and cancerous cells. In response, 
tumors have developed their own 
suite of mechanisms to evade 
immune detection. 
Fortunately, researchers are 
gaining a better understanding of 
the interaction between immune 
effector cells and tumors. New, 
promising treatment strategies 
that stimulate durable, immune-
mediated tumor regression are now 
being used clinically. While these 
new immuno-oncology strategies 
are highly encouraging, they are not 
broadly efficacious across all cancers. 
Research to improve immuno-
oncology-based therapies would 
benefit from a humanized, small 
animal model testing platform. The 
platform would allow scientists to 
better understand human immune 
and tumor cell interactions and 
enable preclinical testing of new 
therapies that have a higher 
likelihood for clinical success.
Here, we review methods 
tumors use to evade immune-
mediated elimination, current 
immunotherapies being tested 
in the clinic, and limitations to 
developing novel therapies given the 
mouse models currently available. 
Importantly, we demonstrate the 
utility of a new mouse platform−
Onco-hu−that allows the study 
of patient-derived xenograft 
(PDX) tumors in the context of 
a humanized immune system for 
immuno-oncology preclinical 
research (Figure 1). Humanized NSG 
mice (both NSG and NSG-SGM3 
hosts) support the growth of PDX 
tumors, respond to SOC treatments, 
and exhibit immune-mediated tumor 
regression following treatment with 
a check-point inhibitor. These results 
support the use of humanized NSG 
mice as a preclinical bridge for new 
immuno-oncology therapies. 
Tumor Evasion of 
Human Immunity
The immune system is a major 
regulator of anticancer therapy 
response and resistance. Many early 
tumors are thought to be eradicated 
by host immune cells following 
recognition of unique antigens 
expressed on the tumor cell’s 
surface. Immune cell involvement is 
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largely dictated by tumor type and 
molecular signature (Coffelt and 
de Visser, 2015). Indeed, advanced 
patient-derived tumor samples often 
carry human immune effector cells 
as passengers. One such population 
is tumor infiltrating lymphocytes 
(TILs), which are typically CD8+ 
cytotoxic T lymphocytes (CTLs). 
TILs have been isolated from tumors, 
expanded ex vivo, and adoptively 
transferred back into the patient 
to take advantage of their tumor-
specific killing ability (Restifo et al., 
2012). The adoptive immunotherapy 
approach has been successful 
in treating some patients with 
metastatic melanoma (Rosenberg 
et al., 2011) and has expanded to 
the treatment of common epithelial 
cancers (Rosenberg and Restifo, 
2015). However, it is not universally 
effective in eradicating tumors. 
The absence or loss of tumor 
killing activity, both pre- and post-
adoptive transfer, can be explained 
by multiple modes of immune 
suppression. 
Two immunosuppressive pathways 
that have been implicated in TIL 
inhibition are mediated by cytotoxic 
T lymphocyte antigen 4 (CTLA-4) 
and by programmed death 1 (PD-1) 
(Ahmadzadeh et al., 2009; Baitsch 
et al., 2011). Both are known as 
“check-point” pathways because they 
prevent the loss of immune tolerance 
under normal conditions. Human 
monoclonal antibodies Yervoy 
(Ipilimumab) and Tremelimumab 
have been developed to bind 
CTLA-4 and prevent its interaction 
with CD80 or CD86 on antigen 
presenting cells, causing a block 
in T-cell inhibitory signaling. The 
current consensus is that CTLA-4 
blockade allows CD80 or CD86 to 
bind with CD28, thereby activating 
a key T-cell co-stimulatory pathway. 
Ipilimumab and Tremelimumab 
are the first “checkpoint inhibitors” 
to advance into clinical trials for 
treating melanoma (Pardoll, 2012). 
Both antibodies promote longer-
term patient survival in a fraction of 
patients, a fact that has stimulated 
widespread interest to find methods 
to activate other native immune 
modalities to target tumors.
PD-1 and its ligand PD-L1 are part 
of another key check-point pathway 
that has been manipulated to 
CD34+  HSC NSG
Humanized NSG
PDX Tumor or Cell Line
Tumor-bearing Humanized NSG
Irradiation
Figure 1. Onco-Hu: A revolutionary 
immuno-oncology mouse platform.  
Tumor-bearing humanized NSG mice. CD34+ 
hematopoietic stem cells are intravenously 
injected into sublethally irradiated 3-week 
old immunodeficient NSG or NSG-SGM3 
mice. After confirmation of human 
leukocyte engraftment (including T cells) in 
peripheral blood at 15 weeks of age, mice 
are then engrafted with patient-derived 
xenograft tumors or tumor cell lines. Study 
enrollment for immuno-oncology testing 
may begin shortly after tumors and reach a 
desired size.
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enhance CTL-mediated tumor destruction 
(Ostrand-Rosenberg et al., 2014; Pauken 
and Wherry, 2015). The development of 
anti-PD-1 blocking antibodies was spurred 
by three key reports: mice with a null 
mutation in PD-1 develop an autoimmune 
syndrome (Nishimura et al., 1999), TILs 
upregulate PD-1 and subsequently become 
anergic (Ahmadzadeh et al., 2009), and 
many tumor types express PD-L1 (Zou 
et al., 2008). In early clinical trials, 28% 
of advanced melanoma patients who 
were refractory to anti-CTLA-4 antibody 
treatment responded to an anti-PD-1 
monoclonal antibody (Hamid et al., 
2013). Further, when both anti-PD-1 and 
anti-CTLA-4 check-point inhibitors were 
combined, 53% of patients responded 
favorably (Wolchok et al., 2013). 
Immunotherapeutics that inhibit immune 
regulatory pathways such as anti-CTLA-4 
and anti-PD-1, have initiated a new era 
in the treatment of cancer (Coffer and de 
Visser, 2015). As of December 2015, there 
are over 20 anti-PD-1/PD-L1 antibodies 
in clinical trials (Gandini et al., 2016). In 
fact, as of 2016, two anti-PD-1 check-point 
inhibitors have been approved for the U.S. 
market: Prembrolizumab (Keytruda) and 
Nivolumab (Optivo). Both are currently 
entering clinical trials to test their efficacy 
Table 1. Tumor Associated Macrophage (TAM) Immune Suppression
TAM Phenotype Effect
Increased PD-L1 Suppressed CTL activation
Increased IL-10 Stimulation of TH2 cells
Decreased IL-12 Suppression of T cells
Increased CCL22 Attraction of TReg cells
Increased Tek (TIE2) Increased angiogenesis
against abroad range of tumor types. Since 
CTLA-4 and PD-1 regulate distinct inhibitory 
pathways, concurrent combination therapy is 
often more efficacious than either treatment 
alone (Sharma and Allison, 2015).
Tumors use other mechanisms to evade 
immune responses. For example, the highly 
inflammatory microenvironment of the 
tumor recruits tissue-resident macrophages 
and peripheral blood monocytes. These 
myeloid cells receive tumor-derived signals 
that alter gene expression and phenotype 
(Gabrilovich et al., 2012 and Ostuni et al., 
2015). One myeloid cell subpopulation 
that develops in the tumor is the tumor-
associated macrophages (TAM). TAMs 
are an abundant population of leukocytes 
in solid tumors. In many settings, TAMs 
fuel, rather than limit, tumor progression 
(Ostuni et al., 2015). TAMs suppress TIL 
activity and increase tumor angiogenesis 
by the mechanisms presented in Table 1, 
creating a hospitable microenvironment 
that favors cancer outgrowth. TAMs also 
recruit and stimulate regulatory T cells (T
reg
) 
and T-helper 2 cells (T
H
2) lymphocytes 
contributing to strong immunosuppressive 
actions in the tumor. These cells are 
normally associated with maintenance of 
immune tolerance. 
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Table 2. Myeloid Derived Suppressor Cell (MDSC) Immune Suppression
MDSC Phenotype Effect
Increased ARG1 & NOS2 (iNOS) Suppressed CTL activation; TCR down-regulation; decreased 
proliferation
Increased Reactive Oxygen Species (ROS) Suppressed CTL activation; TCR down-regulation; decreased IL-2R 
signaling
Increased ADAM17 Decreased CD62L on CD4 & CD8 T cells; impaired lymph node 
trafficking
Co-stimulation & Soluble factors Activation and expansion of TReg cells
Other myeloid cells found in tumors 
include myeloid-derived suppressor 
cells (MDSCs). MDSCs represent a 
heterogeneous group of immature cells 
that include precursors of macrophages, 
granulocytes, and dendritic cells, 
defined by their ability to suppress 
T cell proliferation and to promote 
angiogenesis (Coffelt and de Visser, 
2015). As shown in Table 2, MDSCs 
use a spectrum of immunosuppressive 
mechanisms to help tumors evade 
immunity. Most of their effects are 
directed at suppressing T cells. 
Other immune cell populations 
important in tumor immunity include 
dendritic cells (DCs) and natural 
killer (NK) cells. DCs are considered 
“professional antigen presenting cells” 
and are capable of processing unique 
tumor-specific antigens to activate T 
and B cells. DCs, therefore, are at the 
center of research devoted to developing 
tumor vaccines and to expanding tumor-
specific CTLs ex vivo for subsequent 
adoptive immunotherapy (Palucka et 
al., 2012). NK cells have unique cell-
surface receptors that are important 
for immune surveillance of self-tissues 
and whose activities are mediated 
by binding of HLA class I antigen-
presenting molecules that are found on 
most normal cells and tumors. Tumors 
that retain HLA class I expression evade 
NK cell-mediated cytotoxicity, but 
those that lose expression are no 
longer recognized by NK cells as 
“self” and are killed. Compounds 
that promote NK cell activation and 
adoptive immunotherapies that use 
allogeneic NK cells are active areas of 
preclinical and clinical investigation 
(Vivier et al., 2012).
New Therapeutics 
in the Pipeline
As the information above suggests, 
our knowledge of immune cell 
function and interactions with tumor 
cells is improving. Delineation of 
the basic mechanisms that underlie 
these interactions has uncovered 
several potential strategies through 
which immune cells might be 
manipulated to enhance their 
antitumor activity. Some of the most 
promising examples are outlined in 
Table 3. 
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Table 3. Current Approaches to New Immuno-Oncology Therapeutics
Monoclonal Antibodies
Block ligands & receptors between cells
Bind receptors to activate pathways
Target cells for destruction by ADCC
Antibody-drug conjugates
Bispecific T-cell Engager (BiTE) 
Antibodies
Promotion of T cell killing of target
Chimeric Antigen Receptors (CARs) Promotion of T or NK cell killing of target
Adoptive Cell Transfer
Tumor infiltrating lymphocytes (TIL)
TCR gene therapy
Allogeneic donor lymphocyte infusion (DLI)
Allogeneic NK cell infusion
Antigen loaded dendritic cells
Vaccination Tumor-specific antigen stimulation
For example, monoclonal antibodies 
can block or enhance ligand-receptor 
interactions between cells, act as 
agonists or antagonists, target cellular 
destruction by antibody-dependent 
cellular cytotoxicity (ADCC), and deliver 
conjugated drug payloads to specific 
target cells. Bispecific T-cell Engager 
(BiTE) therapy uses binding specificity 
regions from two antibodies fused into a 
single molecule. These molecules directly 
bind CTLs to antigens on tumor cells to 
enhance tumor killing (Stone, et al., 2012 
and Laszlo et al., 2014).
Additionally, the ability to genetically 
engineer lymphocytes to express 
conventional T-cell receptors or chimeric 
antigen receptors (CARs) has extended 
the application of adoptive cell transfer 
immunotherapies (Rosenberg and 
Restifo, 2015). CAR T-cell therapy is 
an exciting and powerful technology 
that was designated as a Breakthrough 
Therapy in 2014 by the U.S. Food and 
Drug Administration (FDA). A CAR is 
composed of the antigen-recognition 
portion of an antibody conjugated to the 
transmembrane and signaling domains 
of a T-cell receptor. When expressed 
on T-cells isolated from a patient, 
CARs recognizing cancer-associated 
antigens can be infused back into the 
bloodstream. Such CAR T-cells have 
the ability to decrease tumor burden 
and increase survival. CAR T-cell 
therapy has made great strides in 
treating CD19 positive leukemias and 
lymphomas which have previously 
failed all other chemotherapeutic 
interventions (Dai, et al., 2016). 
Future developments in CAR therapy 
will focus on the unique barriers to 
treating solid tumors, expressing 
CARs in NK cells, and combination 
therapies with check-point inhibitors 
(Beavis et al., 2015, Vanneman and 
Dranoff, 2012, Rezvani et al., 2015, 
and John et al. 2013). 
Allogeneic (i.e., mismatched) 
donor lymphocyte infusion (DLI) 
creates a graft-versus-tumor effect 
and has been successful in treating 
many patients with leukemia. A 
similar approach is being explored 
using allogeneic NK cells (Vivier 
et al., 2012). Greater knowledge of 
tumor-specific antigens has been 
accumulating such that tumor 
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antigen peptides might be used to 
prime DCs and thereby stimulate their 
adaptive immune responses prior to 
adoptive transfer. Alternatively, these 
antigens might be injected directly as 
potential vaccines to amplify endogenous 
tumor-specific T-cell responses (Miller 
and Sadelain, 2015). All of these new 
approaches require appropriate in vivo 
preclinical evaluation prior to testing 
in humans in order to validate their 
mechanism of actions, efficacy, and 
safety. 
The Challenge of 
Developing New 
Therapeutics
Laboratory mice represent one of 
the most valuable research platforms 
for characterizing in vivo immune-
tumor interactions and for testing 
new therapeutics. Immune-competent 
mice can be genetically engineered 
to develop tumors spontaneously, or 
can be transplanted with tumors from 
a syngeneic donor or tumor cell line. 
Mouse genetics, immunity, and tumor 
development share many similarities 
with humans, but distinct differences 
exist. For example, humans and mice 
differ in peripheral blood lymphocyte 
distribution and their neutrophils 
respond differently in innate and 
adaptive immune stimulation (Mestas 
and Highes, 2004). MDSCs in mice are 
primarily of the less-immunosuppressive 
polymorphonuclear variety, while those 
in humans are commonly the more 
suppressive monocytic type (Gabrilovich 
et al., 2012). The etiology of tumor 
development in the two species 
is also not necessarily identical 
(Rangarajan and Weinberg, 2003).
Additionally, mice and humans 
exhibit differences in receptor-
ligand homologies and affinities 
such that reagents showing efficacy 
in the mouse do not necessarily 
show the same efficacy in the clinic. 
Inbred mice, also, are genetically 
uniform, which greatly enhances 
their scientific utility with respect 
to drug specificity and therapeutic 
reproducibility, but humans are 
genetically diverse. Human genetic 
diversity can dilute efficacy or 
uncover previously unobserved 
off-target toxicities. In some cases, a 
therapeutic developed in the mouse 
may need to be re-engineered and 
re-tested in a more human-specific 
system. Such efforts can be expensive 
and time-consuming.
Given the challenges of testing 
novel immuno-oncology therapies 
in mice, researchers at The Jackson 
Laboratory have employed a highly 
immunodeficient mouse, called 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, 
005557), that is capable of engrafting 
human hematopoietic stem cells 
and supports the development 
and function of multiple aspects 
of human immunity (jax.org/
humanized-mice). 
In addition, JAX In Vivo 
Pharmacology Services has recently 
expanded its humanized mouse 
models by employing a new NSG 
variant, NSG-SGM3 (NOD.Cg-
Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3, 
CSF2, KITLG)1Eav/MloySzJ, 
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013062). NSG-SGM3 mice are NSG 
mice that express human hematopoietic 
cytokines: stem cell factor (SCF), 
also known as Steel Factor gene and 
Kit Ligand, granulocyte/macrophage-
stimulating factor (GM-CSF), and 
interleukin-3 (IL-3), all driven by a 
human cytomegalovirus promoter/
enhancer sequence. Triple transgenic 
NSG-SGM3 mice constitutively produce 
2-4 ng/ml serum levels of human 
SCF, GM-CSF, and IL-3, providing 
cell proliferation and survival signals 
that become more measurable over 
time. These mice support the stable 
engraftment of CD33+ myeloid lineages, 
and several types of lymphoid cells.  As a 
result, NSG-SGM3 mice allow superior 
engraftment of diverse hematopoietic 
lineages compared to other existing 
models.
Both NSG and NSG-SGM3 mice 
support co-engraftment of both human 
immune cells and a wide range of 
human PDX tumors. We demonstrate 
that PDX tumors grown in the context 
of humanized immune systems respond 
to standard-of-care chemotherapeutics 
and to the checkpoint inhibitor Keytruda 
(Prembrolizumab), establishing 
humanized NSG mice as a new 
preclinical platform for testing human-
specific immuno-oncology therapeutics. 
Meeting the Need 
with NSG and 
NSG-SGM3 Mice
At The Jackson Laboratory, 
humanized mice are created by first 
sub-lethally irradiating NSG (hu-
CD34-NSG™) or NSG-SGM3 (hu-
CD34-NSG™-SGM3) mice at 3-4 
weeks of age, followed by subsequent 
tail vein injection of human CD34+ 
HSCs isolated from cord blood. 
Peripheral blood (PBL) engraftment 
is validated 12 weeks later. NSG mice 
support multi-lineage engraftment 
and human immune cell homing into 
nearly all of the appropriate organs 
and tissues, including host bone 
marrow, thymus, spleen, and PBL (as 
summarized in Figure 2 and Table 4, 
Ishikawa et al., 2005; Tanaka et al., 
2012). 
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Table 4. Human Multi-
Lineage Engraftment in 
hu-CD34-NSG 
Data provided by JAX® In Vivo 
Pharmacology Services, The 
Jackson Laboratory.
Figure 2. Humanized CD34+ 
NSG mice support multilineage 
engraftment of human cells, 
including B cells, T cells, dendritic 
cells and monocytes. 
NSG mice injected with human 
hematopoietic stem cells show very robust 
engraftment efficiencies measured by flow 
cytometry using cell specific markers of 
human leukocytes [A] Percent of human 
viable cells in bone marrow and [B] Percent 
of human viable cells in spleen. Data 
provided by JAX® In Vivo Pharmacology 
Services.
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Figure 3. Comparison in 
engraftment between NSG and 
NSG-SGM3 (cells/μL) as measured 
in peripheral blood.  
(A) Total huCD45+ donor cell count, (B) 
Total huCD33+ myeloid cell count, (C) Total 
huCD19+ B cell count, (D) Total huCD3+ 
T cell count, (E) Total huCD3+CD8+ T 
cell count, and (F) Total huCD3+CD4+ T 
cell count. Data provided by JAX® In Vivo 
Pharmacology Services, The Jackson 
Laboratory. 
Compared to the humanized NSG™ 
model, humanized NSG™-SGM3 
mice have increased cell counts 
of the following human immune 
cell populations (as summarized 
in Figure 3, and Wunderlich et al., 
2010; Billerbeck et al., 2011) 
• CD33+ myeloid cells
• Hematopoietic stem cells
• Myeloid progenitor cells
• Mast cells
• Myeloid dendritic cells
• T cells (CD3+)
• T helper cells (CD4+)
• T cytotoxic cells (CD8+)
• T regulatory cells (CD4+, 
CD25+, FoxP3+)
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T Cells
In addition to human immune cell 
development, hu-CD34-NSG have been 
functionally validated. In particular, 
immature human T-cell progenitors 
(CD4+ CD8+ double positive cells) 
produced in the bone marrow of hu-
CD34-NSG mice are found in the thymus 
along with mature CD4+ and CD8+ 
single positive T cells (Ishikawa et al., 
2005). The mature CD4+ T-helper 
cells and CD8+ CTLs then leave the 
thymus and populate the PBL and spleen. 
Together, these observations demonstrate 
that the cells are undergoing thymic 
TCR selection (self-versus-non-self) and 
homing to appropriate tissues. 
To confirm the cytotoxic activity of the 
human T cells, these cells were harvested 
from the spleens of engrafted mice, 
expanded clonally ex vivo by growth 
with allogeneic target cells, and then 
challenged with allogeneic target cells 
in a chromium release cytotoxicity assay 
(Ishikawa et al., 2005). CD4+ T cells 
recognized targets in the context of class 
II antigens and CD8+ T cells recognized 
targets in the context of class I antigens, 
as expected of normal, mature human T 
cells. 
Hu-CD34-NSG mice also demonstrate 
delayed-type hypersensitivity (DTH), 
another measure of T cell function. 
In this assay, hu-CD34-NSG mice 
were sensitized with two abdominal 
applications of dinitrofluorobenzene 
(DNBF) and one week later were 
challenged by topical application of 
DNBF to the ear pinna. An in vivo T cell 
mediated pro-inflammatory response was 
observed by measuring the swelling of 
the pinna. Moreover, this response 
was blocked by hydrocortisone (JAX 
In Vivo Pharmacology Services; data 
not shown).
B Cells
In addition to T cell function, B cell 
function in hu-CD34-NSG mice 
was examined by immunization 
with ovalbumin to stimulate 
immunoglobulin production. 
The human B cells responded by 
producing ovalbumin-specific IgM 
but only minimal IgG (Ishikawa et 
al., 2005). A current limitation of 
this platform is a paucity of human 
cell populations within peripheral 
lymph nodes and poor development 
of germinal centers. These both 
are necessary for the development 
of the memory and plasma B cells 
that are responsible for robust 
immunoglobulin class switching to 
IgG. Additionally, NSG mice are C5 
complement deficient. Although the 
absence of hemolytic complement 
activity supports more robust human 
cell engraftment in NSG, it prevents 
complement dependent cytotoxicity 
(CDC) responses stimulated by 
antibody binding to target cells. 
Myeloid Cells
The hu-CD34-NSG mice also 
develop the full spectrum of myeloid 
cell lineages with their appropriate 
functional activities (Tanaka et al., 
2012). Human macrophages isolated 
from the bone marrow and lung 
of engrafted mice are capable of 
phagocytosis of fluorescent beads 
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and are cytotoxic to S. typhimurium 
when stimulated with interferon gamma 
(INF-γ). Macrophages develop pro-
inflammatory responses to bacterial 
lipopolysaccharides (LPS) through Toll-
like receptors. The human monocytes/
macrophages in hu-CD34-NSG express 
TLR2 and TLR4, and when the mice are 
challenged with LPS, multiple human 
pro-inflammatory molecules are detected 
in plasma, demonstrating an in vivo 
functional response (Tanaka et al., 2012). 
Neutrophils play an important role in 
innate immunity and in tumor biology, 
by developing into MDSC. Human 
neutrophils, defined by the markers 
CD15+, CD33 low, and HLA-DR-, 
represent 35% of the human cells in bone 
marrow and 1-5% in the spleen of hu-
CD34-NSG mice (Tanaka et al., 2012). 
Human CD66b+ neutrophils account for 
less than 1% in PBL but increase to 2.6% 
after in vivo treatment with granulocyte 
colony stimulating factor (Coughlin et 
al., 2012). The marker CD63 is expressed 
in azurophilic granules of neutrophils, 
and human neutrophils in mice treated 
with LPS increase CD63 expression, 
indicating degranulation activity. LPS 
also stimulates an increased respiratory 
response and causes human neutrophils 
to accumulate in the lung, mimicking 
bacterial-induced sepsis. These results 
demonstrate the human neutrophils in 
hu-CD34-NSG mice are functional. 
Natural Killer Cells 
Lastly, hu-CD34-NSG mice have CD3-
NKp46+ NK cells that represent 1-3% 
and 7% of human cells in the spleen 
and lung, respectively (Strowig et al., 
2010). The majority of these NK 
cells are immature NKp46+ CD56- 
cells, but they can be induced to 
mature into NKp46+CD56+ cells 
when treated with interleukin 15 
(IL-15). Human NK cells isolated 
from hu-CD34-NSG spleens de-
granulate and produce IFN-γ in 
vitro when treated with IL-15 and 
provided K562 cells as targets. K562 
is a human erythroleukemia cell 
line that expresses NK recognition 
molecules NCR, NKG2D, and 
DNAM. These data provide evidence 
that humanized NSG mice produce 
NK cells that can be activated and 
respond to cells recognized as non-
self.
Given the abundance of functional 
human immunity reported in the 
hu-CD34-NSG mice, it was predicted 
that these mice would rapidly reject 
any non-HLA matched human 
PDX tumor that was co-engrafted 
subcutaneously. As described above, 
however, there is ample published 
evidence for multiple mechanisms 
by which tumors evade immunity. 
The following data provide clear 
evidence that hu-CD34-NSG mice 
can efficiently engraft both human 
cancer cell lines and diverse human 
PDX tumors that are not HLA 
matched to the hematopoietic donor 
cells used to humanize the NSG host. 
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Onco-Hu: 
Humanized NSG 
and NSG-SGM3 
Mice Engraft  
Non-HLA Matched 
Human Tumors
Initial experiments evaluated whether 
human tumors would grow in humanized 
NSG mice that had been engrafted 
with allogenic human HSC. Breast, 
lung, and sarcoma PDX tumors were 
implanted subcutaneously into NSG or 
hu-CD34-NSG mice with established 
and functionally mature human immune 
cells derived from an HLA mismatched 
human HSC donor (Figure 4). All three 
tumors showed robust growth and no 
obvious indication of rejection. At study 
termination, tumors were analyzed by 
flow cytometry for the presence of TILs. 
Interestingly, all three tumors contained 
human CD4+ and CD8+ T cells, but few 
CD19+ B cells were detected (Figure 
5). The failure of the TILs to slow tumor 
growth in the hu-CD34-NSG recipients 
suggests that these T-cells may have 
become anergic, similar to strategies 
tumors use to evade human immunity, as 
described above. 
These results demonstrate that hu-
CD34-NSG mice support non-HLA 
matched tumor growth and that the 
presence of human immune cells does 
not significantly impact tumor take or 
growth rates.
Figure 4. Presence of human immunity does 
not impact human tumor growth. [A] Human 
breast (TM00090), [B] lung (TM00213), and [C] sarcoma 
(TM00381) PDX grew at similar rates in NSG and humanized 
NSG recipients. PDX tumors were not HLA matched to the 
donor hematopoietic cells. Data provided by JAX® In Vivo 
Pharmacology Services, The Jackson Laboratory.
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Figure 5. PDX tumors grown in hu-CD34-NSG mice 
contain tumor infiltrating lymphocytes. [A] Human breast 
(TM00090), [B] lung (TM00213), and [C] sarcoma (TM00381) PDX 
contain CD4+ and CD8+ T-cells, but minimal CD19+ B cells. The 
presence of TILs did not appear to influence tumor growth. Data 
provided by JAX® In Vivo Pharmacology Services, The Jackson 
Laboratory.
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Human Tumors 
in Onco-Hu Mice 
Respond to Therapy
The ability of the humanized NSG 
mice to support the growth of non-
HLA matched human tumors was an 
important finding in the development of 
this preclinical testing platform. Next, we 
asked whether engrafted tumors would 
respond to clinically relevant standard-
of-care (SOC) treatments and whether 
immuno-oncology checkpoint inhibitors 
could reactivate anti-tumor responses in 
the resident human immune cells. 
In a first set of experiments, allogenic 
human breast cancer PDX tumor 
fragments, which exhibited PD-L1 cell 
surface expression on 56.9% of cells 
by flow cytometry, were engrafted 
into hu-CD34-NSG or hu-CD34-NSG-
SGM3 mice and were subsequently 
treated with vehicle, SOC treatments 
(Cisplatin or Doxorubicin), or PD-1 
inhibitor, Keytruda (Figure 6). Cisplatin, 
Doxorubicin, and Keytruda significantly 
reduced tumor growth compared to the 
vehicle control, indicating that both SOC 
and novel immunotherapeutics show 
efficacy in tumor-bearing hu-CD34-NSG 
and hu-CD34-NSG-SGM3 mice. 
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Figure 6. PD-L1 expressing 
allogenic PDX triple negative 
breast cancer responds to 
standard of care therapy and 
Keytruda.   
Human PDX breast tumor (model 
TM00098) grown in either hu-C34 
NSG (A) or hu-CD34-NSG-SGM3 
mice (B) were treated with either 
standard of care therapies (Cisplatin 
or Doxorubicin, as indicated in figure) 
or Keytruda and compared to vehicle 
group. P<0.05 by one-way ANOVA 
followed by Dunnett’s Multiple 
Comparison Test. 
A.
B.
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Similar experiments were performed 
using allogenic human non-small cell 
lung cancer (NSCLC) PDX fragments, 
which exhibited PD-L1 cell surface 
expression on 89.1% of cells by flow 
cytometry (Figure 7). These PDX tumors 
were engrafted into hu-CD34-NSG and 
hu-CD34-NSG-SGM3 mice and treated 
with vehicle, SOC, Keytruda or CTLA-4 
inhibitor, Yervoy. As before, both SOC 
and check-point inhibitors significantly 
reduced tumor growth compared to the 
vehicle control. In the hu-CD34-NSG 
mice, NSCLC PDX tumors were collected 
at study completion and analyzed by 
immunofluorescence. CD8+ T-cells 
had infiltrated Keytruda-treated tumors 
indicating that tumor regression may be 
mediated by cytotoxic T-cells (data not 
shown).
Together, these experiments demonstrate 
that human tumors engrafted in hu-
CD34-NSG and hu-CD34-NSG-SGM3 
mice are able to respond to standard-of-
care chemotherapeutics. An even more 
significant finding, however, is that the 
engrafted tumors appear to evade human 
immunity much as they do in the patients 
from which they were derived. Moreover, 
treatment with a TIL check-point inhibitor 
presumably releases T-cells from anergy 
and stimulates their cytotoxicity towards 
the tumor. These are all very preliminary 
experiments and additional work is needed 
to verify the increased TIL-mediated 
cytotoxicity in the Keytruda-treated samples. 
Nevertheless, these data clearly show the 
hu-CD34-NSG and hu-CD34-NSG-SGM3 
mice as  powerful platforms for gathering 
new insights into the interactions of 
human immune cells and tumors and for 
testing immuno-oncology and combination 
therapies.
Figure 7. Allogenic non-small cell lung cancer (NSCLC) PDX responds to checkpoint 
inhibitor blockade and increases tumor infiltration of cytotoxic T-cells.  
Human PDX lung tumor (model TM00302) grown in either hu-CD34-NSG (A) or hu-CD34-NSG-SGM3 mice (B) 
were treated with either standard of care therapy (Cisplatin) or checkpoint inhibitors (Keytruda or Yervoy) and 
compared to vehicle group.
A. B.
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Accessing 
Humanized Mice, 
Onco-Hu, and PDX 
Tumors
Obtaining access to human sources of 
hematopoietic stem cells and tissues 
remains a strong barrier to widespread 
access and construction of these valuable, 
humanized animal models. Similarly, 
HSC quality can vary considerably from 
donor-to-donor, which can significantly 
impact engraftment efficiency and, 
ultimately, the quality of the humanized 
mice created. To assist scientists in 
gaining ready access to these humanized 
models, The Jackson Laboratory has 
developed our humanized mice resource 
through which we can provide:
• Study-ready cohorts of inventoried 
hu-CD34-NSG and hu-CD34-NSG-
SGM3 mice for immediate shipment 
to your institution.
• NSG mice engrafted with human 
peripheral blood mononuclear cells 
(hu-PBMC NSG and hu-PBMC NSG-
SGM3 mice).
• Onco-Hu mice, humanized NSG and 
NSG-SGM3 mice engrafted with 
PDX tumors.
• Customized drug efficacy studies 
executed by our In Vivo Services 
scientists. 
The hu-PBMC NSG and hu-PBMC 
NSG–SGM3 mice have not been tested 
for growth of human tumors, but may 
prove equally important in developing 
immuno-oncology-based therapies 
for aggressive hematological 
cancers such as AML and other 
leukemias (Theocharides et al 2016). 
Humanized mice from The Jackson 
Laboratory can be imported directly 
into your facility and used in your 
experiments following a standard 
1-2 week acclimation period. The 
engrafted human HSCs are tested 
and free of HIV, Hepatitis B Virus 
(HBV), Hepatitis C Virus (HCV), 
and lymphocytic choriomeningitis 
virus (LCMV).
Further, The Jackson Laboratory has 
partnered with 25 cancer clinics 
nation-wide to provide access to a 
variety of patient-derived xenograft 
cancer models at earlier passage 
stages than any other commercial 
PDX repository. Currently, more 
than 400 unique PDX oncology 
models from either treatment-naive 
or treatment-resistant patients 
have been established in the highly 
immunodeficient NSG mouse 
strain (Figure 8). NSG mice engraft 
primary human tumors that at 
low passage retain the genetic and 
phenotypic heterogeneity typically 
seen in human cancers, offering a 
distinct advantage over other PDX 
hosts. This preclinical platform can 
predict the effectiveness of novel 
therapeutics to treat cancer patients. 
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Figure 8. PDX tumor types available from The Jackson 
Laboratory. Over 400 low passage tumors have been collected and 
grown in NSG mice. Tumors are characterized for gene expression, gene 
deletion, and copy number variation. Growth characteristics and histology 
are available, also.
Perfoming Efficacy 
Studies Using New 
Immunotherapeutics
The Jackson Laboratory can provide 
you with experimental cohorts of any 
of our PDX cancer models engrafted in 
NSG mice or in humanized NSG mice. 
Alternatively, our Ph.D.-trained study 
directors can conduct either standardized 
or fully customizable efficacy studies 
using these models for you at our facility. 
Typical studies that we perform may 
include pilot oncology or immuno-oncology 
efficacy studies for single or combination 
drug dosing, dose-response relationship 
analyses, or compound tolerability studies. 
To assist you in selecting a tumor model, 
detailed descriptions of our PDX tumors 
are available from the Patient Derived 
Xenograft Search Form on the Mouse 
Tumor Biology website: (tumor.informatics.
jax.org).
The idea of harnessing immune cells to fight 
cancer is not new, but only in the past few 
years have scientists demonstrated what a 
game-changer cancer immunotherapy can 
be in the clinic (Mueller 2015). Currently, 
only a subset of patients responds to 
immunotherapy. It is critical to understand 
why. Tumor-bearing humanized NSG and 
NSG-SGM3 mice are a valuable preclinical 
testing platform to address outstanding 
questions in this rapidly advancing 
field: 1) Which tumor types will be most 
responsive to immunotherapy and what 
are the underlying mechanisms? 2) How 
can optimal therapy combinations be 
determined for individual patients? 3) What 
are the mechanisms behind resistance to 
immunotherapy and immunomodulatory 
agents? 4) How can resistance be 
anticipated and prevented? New insights 
will forge the way towards improving 
existing therapies and developing new 
approaches.
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